Recent Investment Analysts’ Ratings Updates for Zymeworks (ZYME)

Zymeworks (NASDAQ: ZYME) has recently received a number of price target changes and ratings updates:

  • 11/13/2026 – Zymeworks had its price target raised by Citizens Jmp from $32.00 to $39.00. They now have a “market outperform” rating on the stock.
  • 11/11/2026 – Zymeworks had its price target raised by Citigroup from $39.00 to $44.00. They now have a “buy” rating on the stock.
  • 11/10/2026 – Zymeworks had its price target raised by TD Cowen from $34.00 to $39.00. They now have a “buy” rating on the stock.
  • 11/10/2026 – Zymeworks had its price target raised by Truist Financial from $35.00 to $36.00. They now have a “buy” rating on the stock.
  • 11/10/2026 – Zymeworks had its price target raised by HC Wainwright from $55.00 to $56.00. They now have a “buy” rating on the stock.
  • 10/27/2026 – Zymeworks had its price target raised by Truist Financial from $34.00 to $35.00. They now have a “buy” rating on the stock.
  • 10/26/2026 – Zymeworks had its “market outperform” rating reaffirmed by Citigroup.
  • 10/23/2026 – Zymeworks had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $52.00 price target on the stock.
  • 10/15/2026 – Zymeworks had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/7/2026 – Zymeworks had its price target raised by Truist Financial from $32.00 to $34.00. They now have a “buy” rating on the stock.
  • 9/29/2026 – Zymeworks had its “buy” rating reaffirmed by Citigroup. They now have a $39.00 price target on the stock, up from $38.00.
  • 9/29/2026 – Zymeworks is now covered by TD Cowen. They set a “buy” rating and a $34.00 price target on the stock.

Zymeworks Trading Down 2.3%

Shares of Zymeworks stock opened at $25.84 on Wednesday. The firm’s 50 day moving average is $27.22 and its 200 day moving average is $25.52. The firm has a market capitalization of $1.78 billion, a PE ratio of 49.69 and a beta of 1.32. Zymeworks Inc. has a 1 year low of $21.52 and a 1 year high of $31.97.

Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. The firm’s revenue was up 828.7% compared to the same quarter last year. As a group, research analysts anticipate that Zymeworks Inc. will post 1.31 earnings per share for the current year.

Insider Buying and Selling at Zymeworks

In related news, insider Paul Moore sold 39,741 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the sale, the insider owned 33,756 shares of the company’s stock, valued at $880,018.92. This trade represents a 54.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Adam Schayowitz sold 13,832 shares of the firm’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the sale, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is currently owned by corporate insiders.

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Read More

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.